Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN…
VANCOUVER, British Columbia, March 18, 2021 (GLOBE NEWSWIRE) — Segra International Corp, a leading cannabis…
San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE”…
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently…
ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over…
– Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with…
Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice…
WOBURN, Mass., March 18, 2021 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural…
CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology…
BIO-Europe Spring 2021 Kempen Life Sciences Conference 4th SACHS Annual Neuroscience Innovation Forum 2021 MADRID,…
Company to host an investor conference call and webcast at 4:30pm ET on that day…
Cary, NC, March 18, 2021 (GLOBE NEWSWIRE) — APIE Therapeutics, a preclinical biopharma company pioneering…
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world…
ATLANTA, March 18, 2021 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical…
– FHD-286 Phase 1 data anticipated as early as year-end 2021 – FHD-609 IND submission…
FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology…
SEATTLE, March 18, 2021 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company…
Pyxis expands developmental capabilities with license to two ADC programs and ADC technology platform toolkit…
MENLO PARK, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒‒ Final Data, Including Bone…